Prise en charge du mésothéliome pleural malin en 2013

J. Margery; W. Gaspard; I. Ngampolo; H. Souhi; H. Le Floch; F. Rivière; C. Marotel; D. Planchard; F. Vaylet

doi:10.1016/S1877-1203(13)70439-7

Prise en charge du mésothéliome pleural malin en 2013

J. Margery, W. Gaspard, I. Ngampolo, H. Souhi, H. Le Floch, F. Rivière, C. Marotel, D. Planchard, F. Vaylet

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

Résumé

Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, secondary to occupational asbestos exposure. Clinical and radiological signs are unspecific. The diagnosis of MPM is based on histology on biopsies best obtained by thoracoscopy. Prophylactic irradiation of chest scars and drains is validated by French guidelines. Surgery, extrapleural pneumonectomy or pleurectomy/decortication, is not recommended outside a clinical trial. Firstline chemotherapy with pemetrexed remains the standard treatment. Bevacizumab is currently tested in an ongoing randomized phase 3 trial, MAPS, ending in late 2013.

Titre traduit de la contribution	Management of malignant pleural mesothelioma in 2013
langue originale	Français
Pages (de - à)	447-451
Nombre de pages	5
journal	Revue des Maladies Respiratoires Actualites
Volume	5
Numéro de publication	5
Les DOIs	https://doi.org/10.1016/S1877-1203(13)70439-7
état	Publié - 1 janv. 2013

mots-clés

Asbestosis
Diagnosis
Mesothelioma
Pleura
Treatment

Accès au document

10.1016/S1877-1203(13)70439-7

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{fd089077b0dc44959cc767fbfe967a0f,

title = "Prise en charge du m{\'e}soth{\'e}liome pleural malin en 2013",

abstract = "Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, secondary to occupational asbestos exposure. Clinical and radiological signs are unspecific. The diagnosis of MPM is based on histology on biopsies best obtained by thoracoscopy. Prophylactic irradiation of chest scars and drains is validated by French guidelines. Surgery, extrapleural pneumonectomy or pleurectomy/decortication, is not recommended outside a clinical trial. Firstline chemotherapy with pemetrexed remains the standard treatment. Bevacizumab is currently tested in an ongoing randomized phase 3 trial, MAPS, ending in late 2013.",

keywords = "Asbestosis, Diagnosis, Mesothelioma, Pleura, Treatment",

author = "J. Margery and W. Gaspard and I. Ngampolo and H. Souhi and {Le Floch}, H. and F. Rivi{\`e}re and C. Marotel and D. Planchard and F. Vaylet",

year = "2013",

month = jan,

day = "1",

doi = "10.1016/S1877-1203(13)70439-7",

language = "Fran{\c c}ais",

volume = "5",

pages = "447--451",

journal = "Revue des Maladies Respiratoires Actualites",

issn = "1877-1203",

number = "5",

}

TY - JOUR

T1 - Prise en charge du mésothéliome pleural malin en 2013

AU - Margery, J.

AU - Gaspard, W.

AU - Ngampolo, I.

AU - Souhi, H.

AU - Le Floch, H.

AU - Rivière, F.

AU - Marotel, C.

AU - Planchard, D.

AU - Vaylet, F.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, secondary to occupational asbestos exposure. Clinical and radiological signs are unspecific. The diagnosis of MPM is based on histology on biopsies best obtained by thoracoscopy. Prophylactic irradiation of chest scars and drains is validated by French guidelines. Surgery, extrapleural pneumonectomy or pleurectomy/decortication, is not recommended outside a clinical trial. Firstline chemotherapy with pemetrexed remains the standard treatment. Bevacizumab is currently tested in an ongoing randomized phase 3 trial, MAPS, ending in late 2013.

AB - Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, secondary to occupational asbestos exposure. Clinical and radiological signs are unspecific. The diagnosis of MPM is based on histology on biopsies best obtained by thoracoscopy. Prophylactic irradiation of chest scars and drains is validated by French guidelines. Surgery, extrapleural pneumonectomy or pleurectomy/decortication, is not recommended outside a clinical trial. Firstline chemotherapy with pemetrexed remains the standard treatment. Bevacizumab is currently tested in an ongoing randomized phase 3 trial, MAPS, ending in late 2013.

KW - Asbestosis

KW - Diagnosis

KW - Mesothelioma

KW - Pleura

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84891401312&partnerID=8YFLogxK

U2 - 10.1016/S1877-1203(13)70439-7

DO - 10.1016/S1877-1203(13)70439-7

M3 - Article

AN - SCOPUS:84891401312

SN - 1877-1203

VL - 5

SP - 447

EP - 451

JO - Revue des Maladies Respiratoires Actualites

JF - Revue des Maladies Respiratoires Actualites

IS - 5

ER -